|
|
The current state of the osteoarthritis drug development pipeline : a comprehensive narrative review of the present challenges and future opportunities |
|---|---|
| Author: | Kim, Heungdeok1; Seo, Jinwon1; Lee, Yunsin1; |
| Organizations: |
1Institute of Bio Innovation Research, Kolon Life Science, Inc., Seoul, South Korea 2Centre for Osteoarthritis Pathogenesis Versus Arthritis, Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK 3Versus Arthritis Centre for Sport, Exercise and Osteoarthritis, University of Oxford, Oxford, UK
4Botnar Research Centre, Nuffield Orthopaedic Centre, Oxford, UK
5Research Unit of Medical Imaging, Physics and Technology, Faculty of Medicine, University of Oulu, Oulu, Finland 6Department of Regenerative Medicine, State Research Institute Center for Innovative Medicine, Vilnius, Lithuania 7Department of Orthopedics and Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands 8Department of Joint Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China 9World Health Organization Collaborating Center for Public Health Aspects of Musculoskeletal Health and Aging, Université de Liège, Liège, Belgium 10Healthcare Research Institute, Kolon Advanced Research Center, Kolon Industries, Inc., 110 Magokdong-ro, Gangseo-gu, Seoul 07793, South Korea |
| Format: | article |
| Version: | published version |
| Access: | open |
| Online Access: | PDF Full Text (PDF, 0.2 MB) |
| Persistent link: | http://urn.fi/urn:nbn:fi-fe2023042839332 |
| Language: | English |
| Published: |
SAGE Publications,
2022
|
| Publish Date: | 2023-04-28 |
| Description: |
AbstractIn this narrative review article, we critically assess the current state of the osteoarthritis (OA) drug development pipeline. We discuss the current state-of-the-art in relation to the development and evaluation of candidate disease-modifying OA drugs (DMOADs) and the limitations associated with the tools and methodologies that are used to assess outcomes in OA clinical trials. We focus on the definition of DMOADs, highlight the need for an updated definition in the form of a consensus statement from all the major stakeholders, including academia, industry, regulatory agencies, and patient organizations, and provide a summary of the results of recent clinical trials of novel DMOAD candidates. We propose that DMOADs should be more appropriately targeted and investigated according to the emerging clinical phenotypes and molecular endotypes of OA. Based on the findings from recent clinical trials, we propose key topics and directions for the development of future DMOADs. see all
|
| Series: |
Therapeutic advances in musculoskeletal disease |
| ISSN: | 1759-720X |
| ISSN-E: | 1759-7218 |
| ISSN-L: | 1759-720X |
| Volume: | 14 |
| Article number: | 1759720X221085952 |
| DOI: | 10.1177/1759720X221085952 |
| OADOI: | https://oadoi.org/10.1177/1759720X221085952 |
| Type of Publication: |
A2 Review article in a scientific journal |
| Field of Science: |
3121 General medicine, internal medicine and other clinical medicine 317 Pharmacy |
| Subjects: | |
| Funding: |
The authors received no financial support for the research, authorship, and/or publication of this article. |
| Copyright information: |
© The Author(s), 2022. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
|
https://creativecommons.org/licenses/by-nc/4.0/ |